Abstract
The characteristics of terbium-161 diethylene triamine penta-acetic acid (DTPA) labelled octreotide with respect to specific binding to somatostatin (octreotide) receptors on rat brain cortex membranes, biological activity, uptake and excretion by isolated perfused rat livers and metabolism in vivo in normal and tumour-bearing rats were determined and compared to those of indium-111 DTPA-octreotide. The results of the binding studies demonstrate that161Tb-DTPA-octreotide is a high-affinity radioligand for somatostatin receptors, with an affinity comparable to that of111In-DTPA-octreotide. Rat growth hormone secretion inhibition experiments showed that161Tb-DTPA-octreotide has a similar potency to111In-DTPA-octreotide.161Tb-DTPA-octreotide appeared to be taken up even less by the isolated perfused rat liver than111In-DTPA-octreotide, as almost no tracer disappeared from the perfusion medium. Furthermore, hardly any radioactivity was found in the liver, and excretion into the bile was negligible. The biodistribution studies showed that for octreotide receptor-positive organs, such as pancreas and adrenals, uptake of161Tb-DTPA-octreotide is lower then that of111In-DTPA-octreotide. However, as the clearance from the blood of the former compound is faster than that of the latter, the tissue/blood ratio is higher in the case of161Tb-DTPA-octreotide than with111In-DTPA-octreotide. Furthermore, these studies demonstrated that the uptake of161Tb-DTPA-octreotide by the renal tubular cells after glomerular filtration can be reduced by administration of lysine or sodium maleate. Increase in urine production before and during the experiment had no effect on the kidney uptake of161Tb-DTPA-octreotide. Finally, it appeared that a maximal labelling efficiency of161Tb-DTPA-octreotide is essential, as with decreasing efficiency the uptake in the octreotide receptor-positive organs decreased, whereas non-specific uptake in the other organs was increased. It is concluded that, on the basis of the favourable physical characteristics of161Tb combined with the in vitro and in vivo studies performed with161Tb-DTPA-octreotide, the latter is a promising radiopharmaceutical for both intraoperative scanning and radiotherapy. Studies in patients need to be performed now to see whether161Tb-DTPA-octreotide can indeed open new therapeutic applications for patients bearing octreotide receptor-positive tumours.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WAP, Kooij PPM, Oei HY, Van Hagen M, Postema PTE, De Jong M, Reubi JC, Visser TJ, Reijs AEM, Hofland LJ, Koper JW, Lamberts SWJ. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.Eur J Nucl Med 1993; 20:716–731.
O'Dorisio TM. In-vivo radiopeptide receptor binding for intraoperative guided surgery.The Update 1994; 1:11–12.
Ahlman H. Intraoperative use of a scintillation detector after injection of111In- DTPA-octreotide in patients with carcinoids, endocrine pancreatic tumours and medullary thyroid carcinoma.The Update 1994; 1:13–15.
Bakker WH, Albert R, Bruns C, Breeman WAP, Hofland LJ, Marbach P, Pless J, Pralet D, Stolz B, Koper JW, Lamberts SWJ, Visser TJ, Krenning EP. [111In- DTPA-D-Phe1]octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumours: synthesis, radiolabelling and in vitro validation.Life Sci 1991; 49:1583–1591.
De Jong M, Bakker WH, Breeman WAP, Van der Pluijm ME, Kooij PPM, Visser TJ, Docter R, Krenning EP. Kinetic handling of [125I-Tyr3]-octreotide and [111In-DTPA-D-Phe1]-octreotide by the isolated perfused rat liver.J Nucl Med 1993; 34:2025–2030.
De Jong M, Bernard HF, Rolleman EJ, Visser TJ, Bakker WH, Breeman WAP, Van der Pluijm ME, Den Hollander JC, Krenning EP. Inhibition of renal tubular uptake of111In-DTPA-octreotide (OctreoScan) in vivo in the rat. Submitted.
Krenning EP, Bakker WH, Kooij PP, Breeman WA, Oei HY, De Jong M, Reubi JC, Visser TJ, Bruns C, Kwekkeboom DJ, Reijs AEM, Van Hagen PM, Koper JW, Lamberts SWJ. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide.J Nucl Med 1992; 33:652–658.
Lamberts SWJ, Krenning EP, Reibi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumours.Endocrine Rev 1991; 12:450–482.
Docter R, De Jong M, Van der Hoek HJ, Krenning EP, Hennemann G. Development and use of a mathematical two-pool model of distribution and metabolism of 3,3′,5-triiodothyro-nine in a recirculating rat liver perfusion system: albumin does not play a role in cellular transport.Endocrinology 1990; 126:451–459.
Reubi JC, Horrisberger U, Essed CE, Jeekel J, Klijn JGM, Lamberts SWJ. Absence of somatostatin receptors in human exocrine pancreatic adenocarcinomas.Gastroenterology 1988; 95:760–763.
Bell GI, Riesine T. Molecular biology of somatostatin receptors.Trends Neurosci 1993; 16:34–38.
Yamada Y, Kagimoto S, Kubota A, Yasuda K, Masuda K, Someya Y, Ihara Y, Li Q, Imura H, Seino S, Seino Y. Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and a fifth (hSSTR5) human somatostatin receptor subtype.Biochem Biophys Res Commun 1993; 195:844–852.
Bruno JF, Berelowitz M. Somatostatin receptors: orphan that found family and function.Mol Cell Neurosci 1993; 4:307–309.
Kaupmann K, Bruns C, Hoyer D, Seuwen K, Lübbert H. Distribution and second messenger coupling of four somatostatin receptor subtypes expressed in brain.FEBS Lett 1993; 331:53–59.
Duncan JR, Welch MJ. Intracellular metabolism of indium-111-DTPA-labeled receptor targeted proteins.J Nucl Med 1993; 34:1728–1738.
Mogensen CE, Selling K. Studies on renal tubular protein reabsorption: partial and near complete inhibition by certain amino acids.Scand J Clin Lab Invest 1977; 37:477–486.
Hammond PJ, Wade AF, Gwilliam ME, Peters AM, Myers MJ, Gilbey SG, Bloom SR, Calam J. Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogue.Br J Cancer 1993; 67:1437–1439.
Pimm MV, Gribben SJ. Prevention of renal tubule re-absorption of radiometal (indium-111) labelled Fab fragment of a monoclonal antibody in mice by systemic administration of lysine.Eur J Nucl Med 1994; 21:663–665.
Worthen HG. Renal toxicity of maleic acid in the rat.Lab Invest 1963; 12:791–801.
Harrison HE, Harrison HC. Experimental production of renal glycosuria, phosphaturia, and aminoaciduria by injection of maleic acid.Science 1954; 120:606–608.
Rogulski J, Pacanis A. Effects of maleate on CoA metabolism in rat kidney.Biochem Nephrol Curr Probl Clin Biochem 1978; 8:406–415.
Hysing J, Ostensen J, Tolleshaug H, Kiil F. Effect of maleate on tubular protein reabsorption in dog kidneys.Renal Physiol 1987; 10:338–351.
Theveniau M, Reisine T. Developmental changes in expression of a 60-kDa somatostatin receptor immunoreactivity in the rat brain.J Neurochem 1993; 60:1870–1875.
Bodenant C, Leroux P, Gonzale BJ, Vaudry H. Transient expression of somatostatin receptors in the rat visual system during development.Neuroscience 1991; 41:595–606.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
de Jong, M., Breeman, W.A.P., Bernard, B.F. et al. Evaluation in vitro and in rats of161Tb-DTPA-octreotide, a somatostatin analogue with potential for intraoperative scanning and radiotherapy. Eur J Nucl Med 22, 608–616 (1995). https://doi.org/10.1007/BF01254561
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF01254561